Management of Endometrial Cancer Based on FIGO Staging
The management of endometrial cancer is fundamentally determined by FIGO stage combined with risk stratification based on histologic type, grade, depth of myometrial invasion, and lymphovascular space invasion (LVSI), with the most recent 2023 NCCN guidelines maintaining the 2009 FIGO staging system while the 2025 ESGO-ESTRO-ESP guidelines have adopted the 2023 FIGO staging incorporating molecular classification 1, 2.
Stage I Disease
Stage IA (Tumor confined to uterus, <50% myometrial invasion)
Low-Risk Group (Stage IA, Grade 1-2 endometrioid, no LVSI):
- No adjuvant therapy required 3, 4, 3
- Standard surgery: Total hysterectomy with bilateral salpingo-oophorectomy 5
- Minimally invasive surgery is preferred 2
Intermediate-Risk Group (Stage IA Grade 3 OR Stage IB Grade 1-2):
- Adjuvant pelvic radiotherapy significantly reduces pelvic/vaginal relapses but does not improve overall survival 3, 4
- Vaginal brachytherapy alone is preferred over external beam radiation due to equivalent control rates with significantly less toxicity 1
- PORTEC-2 demonstrated excellent vaginal and pelvic control with brachytherapy alone in uterine-confined disease 1
High-Intermediate Risk (Age ≥60 years with 2 of 3 factors: deep invasion, Grade 3, or substantial LVSI):
- Adjuvant pelvic radiotherapy or vaginal brachytherapy recommended to reduce locoregional relapse rate >15% 3, 4, 3
- Consider chemotherapy for patients with substantial LVSI 1
Stage IB (≥50% myometrial invasion)
High-Risk Group (Stage IB Grade 3 endometrioid with positive LVSI OR non-endometrioid histology):
- Pelvic radiotherapy recommended for locoregional control 3, 4
- Adjuvant platinum-based chemotherapy significantly improves overall survival and progression-free survival compared to radiotherapy alone 4
- For high-risk histologies (serous, clear cell, carcinosarcoma): Consider chemotherapy followed by radiation or combined modality therapy 1
Critical Pitfall: Stage IB Grade 3 was specifically excluded from PORTEC-2, making vaginal brachytherapy alone controversial in this subset—external beam radiation or combined modality therapy is preferred 1.
Stage II Disease
Stage IIA (Endocervical glandular involvement only)
Stage IIB (Cervical stromal invasion)
- Extended radical hysterectomy, bilateral salpingo-oophorectomy, and lymph node dissection 3, 4
- If extrafascial hysterectomy was performed or high-risk features present: Adjuvant pelvic radiotherapy with or without vaginal brachytherapy 3, 4
- Meta-analysis shows external beam radiation plus vaginal brachytherapy significantly reduces locoregional recurrence versus brachytherapy alone 1
Stage III Disease
Surgical Approach
- Maximal surgical cytoreduction should be considered in patients with good performance status 3, 4, 3
- Standard surgery includes total hysterectomy, bilateral salpingo-oophorectomy, and lymph node staging 2
- Sentinel lymph node biopsy with indocyanine green cervical injection is preferred over systematic lymphadenectomy 2
Adjuvant Therapy
- Pelvic radiotherapy increases pelvic control 3, 4, 3
- Cisplatin and doxorubicin combination chemotherapy significantly improves progression-free survival and overall survival in optimally debulked Stage III disease compared to whole abdominal radiation 3, 4, 3
- Carboplatin and paclitaxel is the preferred alternative due to better toxicity profile 3, 4, 3
Special Consideration: Patients with Stage III disease solely on the basis of positive peritoneal cytology are treated as Stage I or II disease based on other clinicopathological factors 3, 4, 3.
Substaging Implications (FIGO 2023)
- Stage IIIA: Serosa or adnexal invasion
- Stage IIIB: Vaginal or parametrial invasion
- Stage IIIC1: Positive pelvic lymph nodes
- Stage IIIC2: Positive para-aortic lymph nodes
- Micrometastases should be treated as node positive 6
Stage IV Disease
Stage IVA (Bladder or bowel mucosa invasion)
- Maximal surgical cytoreduction if feasible 3, 4, 3
- Combination chemotherapy with carboplatin and paclitaxel 3, 4
- Consider pelvic radiotherapy for local control 3, 4
Stage IVB (Distant metastases)
- Systemic chemotherapy is primary treatment 3, 4, 3
- Carboplatin and paclitaxel combination is standard 3, 4
- Active single agents include cisplatin, carboplatin, anthracyclines, and paclitaxel 3, 4, 3
- Doxorubicin with cisplatin and paclitaxel (with bone marrow support) significantly improves progression-free survival and overall survival but has higher toxicity 3, 4
High-Risk Histologies (All Stages)
For serous, clear cell, carcinosarcoma, undifferentiated carcinoma:
- Infracolic omentectomy should be performed for clinical Stage I and II 2
- Chemotherapy is recommended for Stage I-II high-risk histologies 1, 6
- Consider combined modality therapy (chemotherapy plus radiation) 1
Important Note: GOG 249 trial showed increased nodal recurrence with vaginal brachytherapy plus 3 cycles of chemotherapy versus pelvic radiation in high-risk uterine-confined disease, raising questions about adequate chemotherapy duration 1.
Molecular Classification Integration
The 2025 ESGO-ESTRO-ESP guidelines incorporate molecular classification (POLEmut, MMRd, NSMP, p53abn) into staging and treatment decisions 2:
- POLEmut: Excellent prognosis, may allow de-escalation of adjuvant therapy
- p53abn: Poor prognosis, consider upstaging and intensified treatment
- MMRd: Intermediate prognosis, standard treatment
- NSMP: Risk stratified by grade and other factors
The 2023 NCCN guidelines maintain the 2009 FIGO staging system pending further refinement, though molecular data should be increasingly considered 1, 7.
Lymph Node Assessment
- Sentinel lymph node mapping with ultrastaging is recommended over systematic lymphadenectomy 2, 6
- Isolated tumor cells are treated as node negative; adjuvant therapy based on uterine risk factors 6
- Micrometastases are treated as node positive 6
- If sentinel nodes not detected: Side-specific systematic lymphadenectomy for high-intermediate or high-risk patients 2